Skip to main content

Lab Notes: FMC enters into a $200M bio-acquisition; Virpax going the OTC route again

Virpax is once again taking the OTC route for a new product candidate.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.